Medindia

X

Medivation Announces First Quarter 2010 Financial Results Teleconference and Webcast on May 10, 2010

Monday, May 3, 2010 General News J E 4
Advertisement


SAN FRANCISCO, May 3 Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss first quarter 2010 financial results and provide a general business update on May 10, 2010, at 4:30 p.m. Eastern Time. A press release for the first quarter ended March 31, 2010 will be released after markets close on May 10, 2010.

Interested parties may call 877-303-2523 from the U.S. or +1-253-237-1755 internationally. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A replay of the webcast will be available on the Company's website for 30 days.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer, Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer's and Huntington diseases. Medivation and Pfizer are currently conducting Phase 3 studies of dimebon in both of those diseases. In October 2009, Medivation entered a global agreement with Astellas Pharma Inc. to develop and commercialize MDV3100 for both early- and late-stage prostate cancer. The first Phase 3 clinical trial in the MDV3100 development program, known as the AFFIRM trial, is under way in patients with castration-resistant prostate cancer who have previously been treated with docetaxel-based chemotherapy. For more information, please visit us at www.medivation.com.

SOURCE Medivation, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Genomic Health to Present at JMP Securities Resear...
S
MAQUET Cardiovascular Introduces New VASOSHIELD Pr...